Key result
Pioglitazone treatment for 16 weeks significantly increased total and HMW adiponectin levels in patients with PCOS (P<0.05), correlating with increased insulin-stimulated glucose metabolism.
Why the study?
Does pioglitazone improve adiponectin levels and insulin sensitivity in patients with polycystic ovary syndrome?
Population
30 patients with polycystic ovary syndrome (PCOS) and 14 weight-matched healthy females
Comparison
Pioglitazone 30 mg/day for 16 weeks vs Placebo for 16 weeks
Design
RCT, randomized, placebo-controlled
Follow-up
16 weeks
Authors
Loading...
Supports pioglitazone for insulin resistance in PCOS; confirms adiponectin link in randomized data.
RCT (n=44)
randomized
Does pioglitazone improve adiponectin levels and insulin sensitivity in patients with polycystic ovary syndrome?
p-value: p=<0.05
Pioglitazone increases total and HMW adiponectin in PCOS patients, and the increase in total adiponectin strongly correlates with improved insulin sensitivity.
Glintborg et al. (2007) conducted an RCT in Polycystic ovary syndrome (n=44). Pioglitazone vs. Placebo was evaluated on Total and high molecular weight (HMW) adiponectin levels (p=<0.05). Pioglitazone treatment for 16 weeks significantly increased total and HMW adiponectin levels in patients with PCOS (P<0.05), correlating with increased insulin-stimulated glucose metabolism.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: